Smart Nanoparticles Light Up Cervical Cancer and Strike It With Two Weapons at Once

Cervical cancer remains one of the most common malignant tumors affecting women worldwide, and its incidence and mortality continue to climb despite decades of screening programs. A team of researchers in China has now unveiled a nanoscale therapeutic platform that could change how this disease is detected and treated, combining real-time molecular imaging with chemotherapy in a single injectable particle. Writing in the journal Materials Today Bio, the group describes manganese dioxide nanocarriers that remain inert in the bloodstream, then disassemble inside the hostile chemistry of a tumor to release both a fluorescent signal and a lethal payload. In mouse models of cervical cancer, the system shrank tumors by 86.2 percent, outperforming either of its components alone.

The design begins with a biological insight rather than a materials problem. The team focused on microRNA-155, a short non-coding RNA molecule of just 18 to 25 nucleotides that acts as a molecular switch inside cells. Mining data from The Cancer Genome Atlas, the researchers found that miR-155 is significantly elevated in cervical cancer tissues compared with adjacent normal tissue, and that the same elevation appears in cervical cancer cell lines and in the serum of patients. A receiver operating characteristic analysis yielded an area under the curve of 0.94, indicating strong discriminative accuracy as a diagnostic biomarker. Survival curves told a darker story: patients with high miR-155 expression fared significantly worse than those with low expression, marking the molecule as a prognostic indicator as well.

But the team wanted to know what miR-155 actually does inside cervical cancer cells, not merely where it appears. Through a series of gain- and loss-of-function experiments in CaSki and SiHa cervical cancer cell lines, they showed that suppressing miR-155 slowed cell proliferation, reduced secretion of the clinical tumor marker squamous cell carcinoma antigen, and dramatically curtailed migration and invasion in Transwell and wound healing assays. Conversely, artificially boosting miR-155 made the cells more aggressive. The mechanism traced back to epithelial-mesenchymal transition, the developmental program by which cancer cells shed their adhesive, epithelial identity and acquire the motile, mesenchymal traits that enable metastasis. Overexpression of miR-155 lowered epithelial markers such as E-Cadherin, CK18 and CK19 while raising mesenchymal markers including N-Cadherin and Vimentin, along with the matrix-degrading enzyme MMP-9. Blocking miR-155 reversed the entire pattern.

To find the target through which miR-155 exerts these effects, the researchers cross-referenced databases and prediction tools, then validated candidates with dual-luciferase reporter assays. The answer was ZFPM2, a transcriptional regulator whose messenger RNA carries a binding site for miR-155 in its untranslated region. When miR-155 was present, luciferase activity from the wild-type ZFPM2 reporter dropped sharply; mutating the binding site abolished the effect. A second candidate, RASSF2, showed no direct interaction. ZFPM2 was confirmed to be downregulated in cervical cancer tissues and cell lines, and critically, restoring ZFPM2 expression in cells flooded with miR-155 reversed the proliferative surge and the EMT signature. Bidirectional rescue experiments, in which ZFPM2 was knocked down while miR-155 was inhibited, established a causal miR-155-ZFPM2-EMT axis driving the disease.

In vivo work reinforced the story. Nude mice bearing xenograft tumors derived from cervical cancer cells engineered to express an anti-miR-155 inhibitor developed tumors that grew more slowly and weighed substantially less than controls, with an inhibition rate of roughly 45.6 percent. Tumor tissue from these animals showed restored epithelial markers, diminished mesenchymal markers, elevated ZFPM2, and reduced activity of NF-κB signaling and Gli-1, pathways implicated in cervical cancer progression. The stage was thus set for a therapeutic that attacks miR-155 directly while simultaneously delivering chemotherapy.

The resulting nanoplatform, named MPDM, is a layered construct roughly 225 nanometers in diameter. At its core sits a spherical manganese dioxide nanoparticle, synthesized by reacting potassium permanganate with polyallylamine hydrochloride under optimized conditions that produce particles about 25 nanometers across. This core is wrapped in a shell of polydopamine, a bioinspired polymer prized for its biocompatibility and its adhesive chemistry. The polydopamine layer anchors two cargoes through complementary interactions: negatively charged DNAzyme-substrate probes bind via electrostatic attraction between the nucleic acids and protonated amino groups on the particle surface, while the aromatic rings of the polymer engage the nitrogenous bases of the probes through pi-pi stacking. Methotrexate, a classic antifolate chemotherapy drug with documented activity against advanced and recurrent cervical cancer, is loaded with an encapsulation efficiency reaching 80.15 percent at an optimal one-to-one mass ratio.

The elegance of the system lies in its trigger mechanism. Tumors are chemically distinctive environments, enriched in hydrogen peroxide and glutathione at concentrations far exceeding those of healthy tissue. When MPDM nanoparticles are endocytosed by cancer cells, these small molecules diffuse through pores and defects in the polydopamine shell and attack the manganese dioxide core, degrading it completely. The disintegration releases manganese ions, frees the DNAzyme probes and liberates methotrexate, while the loosened shell accelerates drug escape. The released manganese ions serve a second purpose: they are the essential metal cofactors that activate the DNAzyme, a catalytic single-stranded DNA molecule that, once unlocked by binding to miR-155, cleaves its substrate strand and physically separates a fluorophore from a quencher. The result is a fluorescent beacon that switches on only where miR-155 is present.

The sensing performance was striking. After screening DNAzyme and substrate pairs, the team identified a combination that responded linearly to miR-155 across a broad concentration range, with a detection limit of just 0.3 nanomolar. Specificity tests against six other microRNAs, including miR-21 and miR-205, produced no signal, and only manganese ions, among five metals tested, could activate the probe. Inside cells, the nanoparticles lit up brightly in CaSki and SiHa cancer cells while remaining nearly dark in normal cervical epithelial H8 cells, and the fluorescence tracked miR-155 levels up or down as researchers artificially manipulated them. Interestingly, the DNAzyme treats miR-155 as an allosteric trigger rather than a cleavage target: miR-155 binding unfolds the catalytic core, but the microRNA itself is depleted through functional sequestration and RNase-H-mediated degradation of the DNA-RNA duplex, silencing its oncogenic activity.

Therapeutic testing confirmed that the two modes of attack compound each other. In cultured cells, the full MPDM construct killed more cancer cells than nanoparticles carrying methotrexate alone, while leaving normal H8 cells unharmed, a selectivity attributed to tumor-triggered release rather than passive drug diffusion. Control experiments with mismatched or catalytically inactive DNAzymes confirmed that the enhancement depended on genuine miR-155 silencing. In tumor-bearing mice, intravenously injected nanoparticles accumulated preferentially in tumors, peaking at six hours, and a 21-day treatment course produced tumor inhibition rates of 41.4 percent for the DNAzyme carrier, 62.1 percent for methotrexate alone, and 86.2 percent for the combination. A Bliss independence analysis showed the observed effect exceeded the theoretical additive value of about 77.8 percent, confirming true synergy, likely because EMT suppression sensitizes cells to methotrexate-induced cell-cycle arrest.

Safety data were equally encouraging. Treated mice showed no weight loss, no hemolysis, no histological damage to heart, liver, spleen, lung or kidney, and normal serum markers of liver and kidney function. Inductively coupled plasma mass spectrometry found no significant long-term manganese accumulation in any organ, indicating efficient clearance of the released ions. The authors acknowledge that quantitative decoding of intratumoral miR-155 signals in living animals remains technically challenging due to the depth limits of optical imaging, and that the work validates the platform at the preclinical level. Still, the convergence of a validated oncogenic pathway, a tumor-responsive degradable carrier, and a synergistic dual-mode therapy offers a compelling template for theranostic nanomedicine, not only in cervical cancer but potentially in any malignancy driven by an identifiable microRNA signature.

Subject of Research: Tumor microenvironment-responsive manganese dioxide nanocarriers for miR-155 imaging-guided chemotherapy in cervical cancer

Article Title: Tumor microenvironment-responsive manganese nanocarriers for on-demand release of methotrexate and DNAzyme in MiR-155-driven cervical cancer

Article References: Yang, Z., Zhang, L., Wang, Z., Hu, C., Ruan, D., Zhang, F., Guo, B., Shen, Y., & Wang, F. (2026). Tumor microenvironment-responsive manganese nanocarriers for on-demand release of methotrexate and DNAzyme in MiR-155-driven cervical cancer. Materials Today Bio, 41, Article 103747. https://doi.org/10.1016/j.mtbio.2026.103747

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103747

Keywords: cervical cancer, nanomedicine, theranostics, miR-155, DNAzyme, methotrexate, manganese dioxide, tumor microenvironment, epithelial-mesenchymal transition, ZFPM2, fluorescence imaging, drug delivery